Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Reichman

Rheumatology Culver City, CA Medical Doctor

NPI 1487625562 CMS profile 112000

9808 Venice Blvd, Ste 604, Culver City, CA 90232

Open in the dashboard

General payments

$19,655

138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Reichman of Culver City, CA is reported in the CMS Open Payments database as having received $19,655 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $850 8
2024 General $940 8
2023 General $1,865 19
2022 General $1,244 14
2021 General $1,739 21
2020 General $5,078 16
2019 General $7,939 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Reichman
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Ronald Reichman were reported at $850. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Ronald Reichman Rheumatology median Middle half National median
2019 $7,939 $744 $153–$2,687 $163
2020 $5,078 $462 $98–$2,027 $114
2021 $1,739 $531 $101–$2,153 $132
2022 $1,244 $627 $125–$2,303 $149
2023 $1,865 $741 $145–$2,524 $160
2024 $940 $830 $166–$2,660 $164
2025 $850 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $5,346 18 payments
  2. Janssen Biotech, Inc. $2,250 1 payment
  3. UCB, Inc. $1,916 6 payments
  4. AbbVie, Inc. $1,578 26 payments
  5. Amgen Inc. $1,183 15 payments
  6. Lilly USA, LLC $1,164 14 payments
  7. Janssen Scientific Affairs, LLC $1,162 11 payments
  8. Novartis Pharmaceuticals Corporation $1,148 13 payments
  9. Pacira Pharmaceuticals Incorporated $723 1 payment
  10. ZOLL Medical Corporation $610 1 payment
  11. Other $2,576 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,689 118 payments
  2. Consulting Fee $8,195 6 payments
  3. Travel and Lodging $1,028 10 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $723 1 payment
  5. Education $20 3 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $2,375 2 payments
  2. TALTZ $1,039 13 payments
  3. RINVOQ $937 11 payments
  4. Otezla $729 8 payments
  5. EXPAREL $723 1 payment
  6. COSENTYX Immunology $532 8 payments
  7. COSENTYX Dermatology $499 4 payments
  8. AMJEVITA $440 5 payments
  9. HUMIRA $395 11 payments
  10. Bimzelx $393 3 payments
  11. Other $3,547 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record